STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIIB
  4. [Form 4] BIOGEN INC. Insider Trading Activity

[Form 4] BIOGEN INC. Insider Trading Activity

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Biogen Inc. executive Ginger Gregory, EVP of Human Resources, reported multiple equity award transactions dated 02/06/2026. The filing shows restricted stock units converting into common stock at an exercise price of $0 and related dispositions of common shares at $201.18 per share.

Individual conversions include 1,635, 1,802, and 3,746 restricted stock units, each linked to previously granted awards scheduled to vest in three equal annual installments beginning one year after their respective grant dates in 2023, 2024, and 2025. Following these transactions, Gregory directly holds 22,358.7673 shares of Biogen common stock and 7,494 restricted stock units.

Positive

  • None.

Negative

  • None.
Insider Gregory Ginger
Role EVP, Human Resources
Type Security Shares Price Value
Exercise Restricted Stock Unit 1,635 $0.00 --
Exercise Restricted Stock Unit 1,802 $0.00 --
Exercise Restricted Stock Unit 3,746 $0.00 --
Exercise Common Stock 1,635 $0.00 --
Tax Withholding Common Stock 791 $201.18 $159K
Exercise Common Stock 1,802 $0.00 --
Tax Withholding Common Stock 666 $201.18 $134K
Exercise Common Stock 3,746 $0.00 --
Tax Withholding Common Stock 1,132 $201.18 $228K
Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct); Common Stock — 19,399.767 shares (Direct)
Footnotes (1)
  1. Includes 166.6667 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2025. The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023. The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gregory Ginger
(Last) (First) (Middle)
BIOGEN INC.
225 BINNEY ST.
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Human Resources
3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/06/2026 M 1,635 A $0 19,399.7673(1) D
Common Stock 02/06/2026 F 791 D $201.18 18,608.7673 D
Common Stock 02/06/2026 M 1,802 A $0 20,410.7673 D
Common Stock 02/06/2026 F 666 D $201.18 19,744.7673 D
Common Stock 02/06/2026 M 3,746 A $0 23,490.7673 D
Common Stock 02/06/2026 F 1,132 D $201.18 22,358.7673 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit $0 02/06/2026 M 1,635 (2) 02/08/2026 Common Stock 1,635 $0 0 D
Restricted Stock Unit $0 02/06/2026 M 1,802 (3) 02/07/2027 Common Stock 1,802 $0 1,802 D
Restricted Stock Unit $0 02/06/2026 M 3,746 (4) 02/06/2028 Common Stock 3,746 $0 7,494 D
Explanation of Responses:
1. Includes 166.6667 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2025.
2. The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023.
3. The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.
4. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.
/s/ Wendell Taylor, attorney in fact for Ginger Gregory 02/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR